

---

## OTX015

产品编号: D50857

CAS: 202590-98-5

分子式: C<sub>25</sub>H<sub>22</sub>ClN<sub>5</sub>O<sub>2</sub>S

纯度: ≥98%

InChi: InChI=1S/C<sub>25</sub>H<sub>22</sub>ClN<sub>5</sub>O<sub>2</sub>S/c1-13-14(2)34-25-22(13)23(16-4-6-17(26)7-5-16)28-20(24-30-29-15(3)31(24)25)12-21(33)27-18-8-10-19(32)11-9-18/h4-11,20,32H,12H<sub>2</sub>,1-3H<sub>3</sub>,1H,27,33)/t20-/m0/s1

InChi Key: GNMUEVRJHCWKTO-FQEVSTJZSA-N

Smiles: CC1=NN=C2[C@H](CC(=O)NC3C=CC(O)=CC=3)N=C(C3=C(SC(C)=C3C)N12)C1C=CC(Cl)=CC=1

外观: 固体粉末

作用通路: Epigenetic Reader Domain

溶解性: DMSO up to 100 mM

保存条件: Store in dry, dark place for one year.

产品介绍: OTX015 is a novel, highly potent, selective and cell permeable inhibitor of the bromodomain and extra terminal (BET) family proteins BRD2, BRD3 and BRD4 with IC<sub>50</sub> of 10-19 nM. It inhibits the growth of a variety of human cancer cell lines with IC<sub>50</sub> ranging from 60 to 200 nM. OTX015 results in rapid down-regulation of c-MYC expression, and show the synergistic anti-proliferative effects in combination with ALK inhibitors in ALKpos ALCL cell lines. In vivo studies using OTX015 have demonstrated efficacy in a range of oncology models. OTX015 is currently in phase I clinical development for oncology indication.